Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.

Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, Blumenthal GM, Bryan W, McKee AE, Pazdur R.

Clin Cancer Res. 2018 Nov 9. doi: 10.1158/1078-0432.CCR-18-2743. [Epub ahead of print]

PMID:
30413526
2.

A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.

Duncan BB, Highfill SL, Qin H, Bouchkouj N, Larabee S, Zhao P, Woznica I, Liu Y, Li Y, Wu W, Lai JH, Jones B, Mackall CL, Bachovchin WW, Fry TJ.

J Immunother. 2013 Oct;36(8):400-11. doi: 10.1097/CJI.0b013e3182a80213.

3.

Outreach to immigrant communities: teaching pediatric residents about access to health care.

Karp RJ, Rhee D, Feldman D, Bouchkouj N.

J Health Care Poor Underserved. 2007 Aug;18(3):510-5.

PMID:
17675709

Supplemental Content

Loading ...
Support Center